Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581970 | 1.00 | DRD2 (0.38) | DRD2SMN1; SMN2RENCACNA1BHDAC4 | |
| SCHEMBL3580866 | 0.82 | SMN1; SMN2 (0.38) | SMN1; SMN2KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL560138 | 0.81 | CACNA1B (0.50) | SMN1; SMN2CACNA1BHDAC4HDAC1HDAC6 | |
| SCHEMBL560137 | 0.81 | CACNA1B (0.50) | SMN1; SMN2CACNA1BHDAC4HDAC1HDAC6 | |
| SCHEMBL8256601 | 0.81 | CACNA1B (0.50) | SMN1; SMN2CACNA1BHDAC4HDAC1HDAC6 | |
| SCHEMBL3576552 | 0.81 | CAPN1 (0.52) | SMN1; SMN2RENCACNA1BHDAC1KMT2A | |
| SCHEMBL3576555 | 0.81 | CAPN1 (0.52) | SMN1; SMN2RENCACNA1BHDAC1KMT2A | |
| SCHEMBL13543713 | 0.75 | TAS1R3 (0.42) | NPSR1 | |
| SCHEMBL3566181 | 0.74 | NPR3 (0.43) | DRD2RENCACNA1BHDAC1KMT2A | |
| SCHEMBL3566178 | 0.74 | NPR3 (0.43) | DRD2RENCACNA1BHDAC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004250-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004250-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | PLK2, PLK4, PLK3 | DRD2 3516/4885SMN1; SMN2 4351/4885REN 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.